|
95% SpO2
|
96% SpO2
|
97% SpO2
|
98% SpO2
|
p
|
---|
PMA < 33
|
n
|
175
|
154
|
150
|
126
| |
Risk > 80 (%)
|
18% (12–23%)
|
12% (7–18%)
|
37% (30–45%)
|
45% (34–54%)
|
< 0.001
|
Risk > 99 (%)
|
7% (3–11%)
|
4% (1–7%)
|
14% (8–20%)
|
25% (18–33%)
|
< 0.001
|
PaO2
|
63 (54–73)
|
62 (54–73)
|
71 (60–88)
|
80 (63–100)
|
< 0.001
|
PMA 33–36
|
n
|
156
|
172
|
190
|
225
| |
Risk > 80 (%)
|
28% (0.21–0.35)
|
26% (19–32%)
|
0.43 (36–50%)
|
0.61 (54–67%)
|
< 0.001
|
Risk > 99 (%)
|
10% (6–15%)
|
13% (8–18%)
|
20% (14–25%)
|
34% (28–40%)
|
< 0.001
|
PaO2
|
68 (61–81)
|
70 (62–81)
|
79 (67–92)
|
86 (73–108)
|
< 0.001
|
PMA > 36
|
n
|
959
|
1156
|
1483
|
1729
| |
Risk > 80 (%)
|
28% (25–31%)
|
42% (39–45%)
|
56% (53–58%)
|
70% (68–72%)
|
< 0.001
|
Risk > 99 (%)
|
14% (10–14%)
|
20% (17–22%)
|
28% (26–30%)
|
42% (41–45%)
|
< 0.001
|
PaO2
|
70 (61–83)
|
76 (65–93)
|
84 (70–103)
|
94 (78–124)
|
< 0.001
|
- Severe hyperoxemia defined as > 99 mmHg. Differences in risk evaluated with chi-square test. PaO2 presented as median (IQR) with differences evaluated with Kruskal-Wallis test. PaO2 pairs within each maturity category are also statistically different (p < 0.001) except the difference between 95 and 96% SpO2 in both the < 33 weeks and 33–36 weeks groups